Log in with your email address username.


[Correspondence] Treating sickle cell anaemia: the TWiTCH trial

We read with interest the results of the TWiTCH trial1 comparing hydroxyurea with transfusions for the treatment of sickle cell disease. As a patient-support charity, we acknowledge the potential of this study to inform and change clinical practice geared towards reducing the risk of childhood stroke associated with sickle cell disease. As strong advocates for patient’s choice, we believe informed choice should remain key to the use and interpretation of this research in clinical practice.